Trondheim

TRONDHEIM, Norway, November 10, 2011 - Financing will be used to further advance preclinical development of APIM Therapeutics' anti-cancer lead compound, ATX-101, in selected tumor indications including blood cancer and solid tumors.

TRONDHEIM, Norway, March 21, 2011 - APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.

TRONDHEIM, Norway, January 10, 2011 - Avexxin AS, a Norwegian pharma company focusing on the development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the closure of a financing round enabling the company to take its lead compound against psoriasis through early clinical development.